Neointimal hyperplasia of ultra-thin stents with microcrystalline sirolimus or durable polymer everolimus-eluting stents: 6-and 24-month results of the DESSOLVE III OCT study

K Milewski, K Takahashi, T Asano, Y Katagiri, M Hochul, PP Buszman, Mariusz Tomaniak, B Gorycki, A Zurakowski, A Janas, A Mlodziankowski, M Kachel, JJ Wykrzykowska, W Wijns, RJ de Winter, PE Buszman, Y Onuma, PW Serruys

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Scopus)

Abstract

Aims: The DESSOLVE III OCT substudy aimed to compare serially neointimal hyperplasia volume obstruction (%VO) between the thin-strut MiStent with early polymer elimination and nine-month sustained drug release from microcrystalline sirolimus and the durable polymer-coated everolimus-eluting XIENCE stent at six and 24 months after implantation. Methods and results: The efficacy endpoint was %VO, calculated as abluminal neointimal volume/stent volume. Thirty-six patients (MiStent 16 patients, 16 lesions; XIENCE 20 patients, 22 lesions) underwent serial OCT evaluation at both six and 24 months. At six months, mean abluminal %VO was significantly lower in the MiStent group than in the XIENCE group (14.54±3.70% vs 19.11±6.70%; p=0.011), whereas the difference in %VO between the two groups decreased at 24 months (20.88±5.72% vs 23.50±7.33%; p=0.24). There was no significant difference in percentage malapposed struts and percentage uncovered struts between the two groups at both time points. Conclusions: In the serial comparative OCT analysis of the MiStent versus the XIENCE, the MiStent showed a more favourable efficacy for preventing neointimal formation with comparable strut tissue coverage, as compared with the XIENCE at six months, but this difference in %VO decreased at 24 months so that the difference in neointima at 24 months was no longer significant.

Original languageEnglish
Pages (from-to)1187-1194
Number of pages8
JournalEuroIntervention
Volume16
Issue number14
DOIs
Publication statusPublished - 2021

Fingerprint

Dive into the research topics of 'Neointimal hyperplasia of ultra-thin stents with microcrystalline sirolimus or durable polymer everolimus-eluting stents: 6-and 24-month results of the DESSOLVE III OCT study'. Together they form a unique fingerprint.

Cite this